Inflammation and p53: A tale of two stresses

Genes and Cancer

Volumn 2, Issue 4, 2011, Pages 503-516

  Gudkov, Andrei V ^a   Gurova, Katerina V ^a   Komarova, Elena A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

aging; apoptosis; cancer; chemokines; cytokines; immune response; infection; NF B; senescence

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARCINOGEN; CBLB 502; CURAXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEPACRINE; NUTLIN 3; PIFITHRIN ALPHA; PROTEIN P53; RADIOPROTECTIVE AGENT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

AGING; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL STRESS; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME REPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALIA; MAMMALIA;

EID: 80051709190     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911409747     Document Type: Article

References (123)

1. Nobel Lectures, Physiology or Medicine 1922-1941. Amsterdam, London, and New York: Elsevier; 1965:.
2. Loffeld RJ,Willems I,Flendrig JA,Arends JW.Helicobacter pylori and gastric carcinoma.Histopathology. 1990;17 (6): 537-41.
3. Stolte M.Helicobacter pylori gastritis and gastric MALT-lymphoma.Lancet. 1992;339 (8795): 745-6.
4. Gelfand M,Weinberg RW,Castle WM.Relation between carcinoma of the bladder and infestation with Schistosoma haematobium.Lancet. 1967;1 (7502): 1249-51.
5. Schwartz DA.Helminths in the induction of cancer: Opisthorchis viverrini, Clonorchis sinensis and cholangiocarcinoma.Trop Geogr Med. 1980;32 (2): 95-100.
6. Chang MH.Hepatitis B virus infection.Semin Fetal Neonatal Med. 2007;12 (3): 160-7.
7. Kiyosawa K,Akahane Y,Nagata A,Furuta S.Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis.Am J Gastroenterol. 1984;79 (10): 777-81.
8. Sherlock S,Fox RA,Niazi SP,Scheuer PJ.Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum.Lancet. 1970;1 (7659): 1243-7.
9. Rook GA,Dalgleish A.Infection, immunoregulation, and cancer.Immunol Rev. 2011;240 (1): 141-59.
10. Dacosta NA,Kinare SG.Association of lung carcinoma and tuberculosis.J Postgrad Med. 1991;37 (4): 185-9.
11. Engels EA,Shen M,Chapman RS, et al.Tuberculosis and subsequent risk of lung cancer in Xuanwei, China.Int J Cancer. 2009;124 (5): 1183-7.
12. Shiels MS,Albanes D,Virtamo J,Engels EA.Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, Beta-carotene cancer prevention study.Cancer Epidemiol Biomarkers Prev. 2011;20 (4): 672-8.
13. Boleij A,Muytjens CM,Bukhari SI, et al.Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer.J Infect Dis. 2011;203 (8): 1101-9.
14. De Flora S,Bonanni P.The prevention of infection-associated cancers.Carcinogenesis. 2011;:.
15. Raimondi S,Lowenfels AB,Morselli-Labate AM,Maisonneuve P,Pezzilli R.Pancreatic cancer in chronic pancreatitis: aetiology, incidence, and early detection.Best Pract Res Clin Gastroenterol. 2010;24 (3): 349-58.
16. Sandhu JS.Prostate cancer and chronic prostatitis.Curr Urol Rep. 2008;9 (4): 328-32.
17. Tamura H,Schulman SA.Barrett-type esophagus associated with squamous carcinoma.Chest. 1971;59 (3): 330-3.
18. Terzic J,Grivennikov S,Karin E,Karin M.Inflammation and colon cancer.Gastroenterology. 2010;138 (6): 2101 e5-14.
19. Adcock IM,Caramori G,Barnes PJ.Chronic obstructive pulmonary disease and lung cancer: new molecular insights.Respiration. 2011;81 (4): 265-84.
20. Chapman EA,Thomas PS,Yates DH.Breath analysis in asbestos-related disorders: a review of the literature and potential future applications.J Breath Res. 2010;4 (3): 034001.
21. Karin M.NF-kappaB as a critical link between inflammation and cancer.Cold Spring Harb Perspect Biol. 2009;1 (5): a000141.
22. Hajishengallis G,Lambris JD.Microbial manipulation of receptor crosstalk in innate immunity.Nat Rev Immunol. 2011;11 (3): 187-200.
23. Lane D,Levine A.p53 Research: the past thirty years and the next thirty years.Cold Spring Harb Perspect Biol. 2010;2 (12): a000893.
24. Karin M.Nuclear factor-kappaB in cancer development and progression.Nature. 2006;441 (7092): 431-6.
25. Levine AJ,Oren M.The first 30 years of p53: growing ever more complex.Nat Rev Cancer. 2009;9 (10): 749-58.
26. Feng Z,Hu W,Rajagopal G,Levine AJ.The tumor suppressor p53: cancer and aging.Cell Cycle. 2008;7 (7): 842-7.
27. Gudkov AV,Komarova EA.Pathologies associated with the p53 response.Cold Spring Harb Perspect Biol. 2010;2 (7): a001180.
28. Lu T,Burdelya LG,Swiatkowski SM, et al.Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells.Proc Natl Acad Sci U S A. 2004;101 (18): 7112-7.
29. IARC p53 Database. Available at: www.IARC.fr/p53/index.html.
30. Goh AM,Coffill CR,Lane DP.The role of mutant p53 in human cancer.J Pathol. 2011;223 (2): 116-26.
31. Goldstein I,Marcel V,Olivier M,Oren M,Rotter V,Hainaut P.Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.Cancer Gene Ther. 2011;18 (1): 2-11.
32. Lee TL,Yang XP,Yan B, et al.A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status.Clin Cancer Res. 2007;13 (19): 5680-91.
33. Scian MJ,Stagliano KE,Anderson MA, et al.Tumor-derived p53 mutants induce NF-kappaB2 gene expression.Mol Cell Biol. 2005;25 (22): 10097-110.
34. Szoltysek K,Pietranek K,Kalinowska-Herok M,Pietrowska M,Kimmel M,Widlak P.TNFalpha-induced activation of NFkappaB protects against UV-induced apoptosis specifically in p53-proficient cells.Acta Biochim Pol. 2008;55 (4): 741-8.
35. Weisz L,Damalas A,Liontos M, et al.Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.Cancer Res. 2007;67 (6): 2396-401.
36. Schneider G,Kramer OH.NFkappaB/p53 crosstalk-a promising new therapeutic target.Biochim Biophys Acta. 2011;1815 (1): 90-103.
37. O'Prey J,Crighton D,Martin AG,Vousden KH,Fearnhead HO,Ryan KM.p53-mediated induction of Noxa and p53AIP1 requires NFkappaB.Cell Cycle. 2010;9 (5): 947-52.
38. Ryan KM,Ernst MK,Rice NR,Vousden KH.Role of NF-kappaB in p53-mediated programmed cell death.Nature. 2000;404 (6780): 892-7.
39. Hudson JD,Shoaibi MA,Maestro R,Carnero A,Hannon GJ,Beach DH.A proinflammatory cytokine inhibits p53 tumor suppressor activity.J Exp Med. 1999;190 (10): 1375-82.
40. Yonish-Rouach E,Resnitzky D,Lotem J,Sachs L,Kimchi A,Oren M.Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.Nature. 1991;352 (6333): 345-7.
41. Gurova KV,Hill JE,Guo C, et al.Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.Proc Natl Acad Sci U S A. 2005;102 (48): 17448-53.
42. Ikeda A,Sun X,Li Y, et al.p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53.Biochem Biophys Res Commun. 2000;272 (2): 375-9.
43. Webster GA,Perkins ND.Transcriptional cross talk between NF-kappaB and p53.Mol Cell Biol. 1999;19 (5): 3485-95.
44. Avantaggiati ML,Ogryzko V,Gardner K,Giordano A,Levine AS,Kelly K.Recruitment of p300/CBP in p53-dependent signal pathways.Cell. 1997;89 (7): 1175-84.
45. Gerritsen ME,Williams AJ,Neish AS,Moore S,Shi Y,Collins T.CREB-binding protein/p300 are transcriptional coactivators of p65.Proc Natl Acad Sci U S A. 1997;94 (7): 2927-32.
46. Egan LJ,Eckmann L,Greten FR, et al.IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium.Proc Natl Acad Sci U S A. 2004;101 (8): 2452-7.
47. Kashatus D,Cogswell P,Baldwin AS.Expression of the Bcl-3 proto-oncogene suppresses p53 activation.Genes Dev. 2006;20 (2): 225-35.
48. Tergaonkar V,Pando M,Vafa O,Wahl G,Verma I.p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy.Cancer Cell. 2002;1 (5): 493-503.
49. Gu L,Findley HW,Zhou M.MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia.Blood. 2002;99 (9): 3367-75.
50. Xia Y,Padre RC,De Mendoza TH,Bottero V,Tergaonkar VB,Verma IM.Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP.Proc Natl Acad Sci U S A. 2009;106 (8): 2629-34.
51. Perkins ND.Integrating cell-signalling pathways with NF-kappaB and IKK function.Nat Rev Mol Cell Biol. 2007;8 (1): 49-62.
52. Huang WC,Ju TK,Hung MC,Chen CC.Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.Mol Cell. 2007;26 (1): 75-87.
53. Tergaonkar V,Perkins ND.p53 and NF-kappaB crosstalk: IKKalpha tips the balance.Mol Cell. 2007;26 (2): 158-9.
54. Schumm K,Rocha S,Caamano J,Perkins ND.Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.Embo J. 2006;25 (20): 4820-32.
55. Shen HM,Tergaonkar V.NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy.Apoptosis. 2009;14 (4): 348-63.
56. Ak P,Levine AJ.p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism.Faseb J. 2010;24 (10): 3643-52.
57. Gu L,Zhu N,Findley HW,Woods WG,Zhou M.Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.J Biol Chem. 2004;279 (50): 52141-9.
58. Kawauchi K,Araki K,Tobiume K,Tanaka N.Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation.Biochem Biophys Res Commun. 2008;372 (1): 137-41.
59. Kawauchi K,Araki K,Tobiume K,Tanaka N.p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation.Nat Cell Biol. 2008;10 (5): 611-8.
60. Kawauchi K,Araki K,Tobiume K,Tanaka N.Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification.Proc Natl Acad Sci U S A. 2009;106 (9): 3431-6.
61. Komarov PG,Komarova EA,Kondratov RV, et al.A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.Science. 1999;285 (5434): 1733-7.
62. Christophorou MA,Martin-Zanca D,Soucek L, et al.Temporal dissection of p53 function in vitro and in vivo.Nat Genet. 2005;37 (7): 718-26.
63. Christophorou MA,Ringshausen I,Finch AJ,Swigart LB,Evan GI.The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.Nature. 2006;443 (7108): 214-7.
64. Evan GI,d'Adda di Fagagna F.Cellular.senescence: hot or what? Curr Opin Genet Dev. 2009;19 (1): 25-31.
65. Logunov DY,Scheblyakov DV,Zubkova OV, et al.Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation.Oncogene. 2008;27 (33): 4521-31.
66. Barykova YA,Logunov DY,Shmarov MM, et al.Association of Mycoplasma hominis infection with prostate cancer.Oncotarget. 2011;:.
67. Yamanishi Y,Boyle DL,Pinkoski MJ, et al.Regulation of joint destruction and inflammation by p53 in collagen- induced arthritis.Am J Pathol. 2002;160 (1): 123-30.
68. Okuda Y,Okuda M,Bernard CC.Regulatory role of p53 in experimental autoimmune encephalomyelitis.J Neuroimmunol. 2003;135 (1-2): 29-37.
69. Davis DW,Weidner DA,Holian A,McConkey DJ.Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung.J Exp Med. 2000;192 (6): 857-69.
70. Ghosh S,Mendoza T,Ortiz LA, et al.Bleomycin sensitivity of mice expressing dominant-negative p53 in the lung epithelium.Am J Respir Crit Care Med. 2002;166 (6): 890-7.
71. Merched AJ,Williams E,Chan L.Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling.Arterioscler Thromb Vasc Biol. 2003;23 (9): 1608-14.
72. Guevara NV,Kim HS,Antonova EI,Chan L.The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo.Nat Med. 1999;5 (3): 335-9.
73. van Vlijmen BJ,Gerritsen G,Franken AL, et al.Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice.Circ Res. 2001;88 (8): 780-6.
74. von der Thusen JH,van Vlijmen BJ,Hoeben RC, et al.Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53.Circulation. 2002;105 (17): 2064-70.
75. Komarova EA,Kondratov RV,Wang K, et al.Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice.Oncogene. 2004;23 (19): 3265-71.
76. Martinez-Cruz AB,Santos M,Garcia-Escudero R, et al.Spontaneous tumor formation in Trp53-deficient epidermis mediated by chromosomal instability and inflammation.Anticancer Res. 2009;29 (8): 3035-42.
77. Frank AK,Leu JI,Zhou Y, et al.The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.Mol Cell Biol. 2011;31 (6): 1201-13.
78. Tavana O,Benjamin CL,Puebla-Osorio N, et al.Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence.Cell Cycle. 2010;9 (16): 3328-36.
79. Donehower LA,Harvey M,Slagle BL, et al.Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.Nature. 1992;356 (6366): 215-21.
80. Komarova EA,Krivokrysenko V,Wang K, et al.p53 is a suppressor of inflammatory response in mice.Faseb J. 2005;:.
81. Liu G,Park YJ,Tsuruta Y,Lorne E,Abraham E.p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury.J Immunol. 2009;182 (8): 5063-71.
82. Scatizzi JC,Mavers M,Hutcheson J, et al.The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages.Eur J Immunol. 2009;39 (3): 820-5.
83. Trakala M,Arias CF,Garcia MI, et al.Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1).Eur J Immunol. 2009;39 (3): 810-9.
84. Gustot T.Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response.Curr Opin Crit Care. 2011;17 (2): 153-9.
85. Gudkov AV,Komarova EA.Prospective therapeutic applications of p53 inhibitors.Biochem Biophys Res Commun. 2005;331 (3): 726-36.
86. Coupienne I,Bontems S,Dewaele M, et al.NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy.Biochem Pharmacol. 2011;81 (5): 606-16.
87. Dey A,Tergaonkar V,Lane DP.Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.Nat Rev Drug Discov. 2008;7 (12): 1031-40.
88. Suzuki J,Ogawa M,Muto S, et al.Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.Expert Opin Investig Drugs. 2011;20 (3): 395-405.
89. Palmero EI,Achatz MI,Ashton-Prolla P,Olivier M,Hainaut P.Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.Curr Opin Oncol. 2010;22 (1): 64-9.
90. Karin M,Cao Y,Greten FR,Li ZW.NF-kappaB in cancer: from innocent bystander to major culprit.Nat Rev Cancer. 2002;2 (4): 301-10.
91. Komarova EA,Gudkov AV.Could.p53 be a target for therapeutic suppression? SeminCancer Biol. 1998;8 (5): 389-400.
92. Komarova EA,Gudkov AV.Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors.Biochem Pharmacol. 2001;62 (6): 657-67.
93. Strom E,Sathe S,Komarov PG, et al.Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.Nat Chem Biol. 2006;2 (9): 474-9.
94. Burdelya LG,Krivokrysenko VI,Tallant TC, et al.An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.Science. 2008;320 (5873): 226-30.
95. Leonova KI,Shneyder J,Antoch MP, et al.A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice.Cell Cycle. 2010;9 (7): 1434-43.
96. Vassilev LT,Vu BT,Graves B, et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004;303 (5659): 844-8.
97. Vassilev LT.p53 Activation by small molecules: application in oncology.J Med Chem. 2005;48 (14): 4491-9.
98. Saddler C,Ouillette P,Kujawski L, et al.Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Blood. 2008;111 (3): 1584-93.
99. Shangary S,Wang S.Targeting the MDM2-p53 interaction for cancer therapy.Clin Cancer Res. 2008;14 (17): 5318-24.
100. Shangary S,Wang S.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.Annu Rev Pharmacol Toxicol. 2009;49:223-41.
101. Groskreutz DJ,Monick MM,Yarovinsky TO, et al.Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells.J Immunol. 2007;179 (5): 2741-7.
102. Dey A,Wong ET,Bist P,Tergaonkar V,Lane DP.Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.Cell Cycle. 2007;6 (17): 2178-85.
103. Schiffrin EJ,Morley JE,Donnet-Hughes A,Guigoz Y.The inflammatory status of the elderly: the intestinal contribution.Mutat Res. 2010;690 (1-2): 50-6.
104. Donehower LA.Using mice to examine p53 functions in cancer, aging, and longevity.Cold Spring Harb Perspect Biol. 2009;1 (6): a001081.
105. Coppe JP,Patil CK,Rodier F, et al.Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.PLoS Biol. 2008;6 (12): 2853-68.
106. Donehower LA.Does.p53 affect organismal aging? J Cell Physiol. 2002;192 (1): 23-33.
107. Campisi J.Cancer and aging: yin, yang, and p53.Sci Aging Knowledge Environ. 2002;2002 (1): pe1.
108. Gottlieb TM,Oren M.p53 in growth control and neoplasia.Biochim Biophys Acta. 1996;1287 (2-3): 77-102.
109. Levine AJ,Hu W,Feng Z.The P53 pathway: what questions remain to be explored?.Cell Death Differ. 2006;13 (6): 1027-36.
110. Krizhanovsky V,Xue W,Zender L,Yon M,Hernando E,Lowe SW.Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology.Cold Spring Harb Symp Quant Biol. 2008;73:513-22.
111. Demidenko ZN,Korotchkina LG,Gudkov AV,Blagosklonny MV.Paradoxical suppression of cellular senescence by p53.Proc Natl Acad Sci U S A. 2010;107 (21): 9660-4.
112. Feng Z,Levine AJ.The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.Trends Cell Biol. 2010;20 (7): 427-34.
113. Korotchkina LG,Leontieva OV,Bukreeva EI,Demidenko ZN,Gudkov AV,Blagosklonny MV.The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.Aging (Albany NY). 2010;2 (6): 344-52.
114. Garcia-Cao I,Garcia-Cao M,Martin-Caballero J, et al."Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally.Embo J. 2002;21 (22): 6225-35.
115. Matheu A,Pantoja C,Efeyan A, et al.Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging.Genes Dev. 2004;18 (22): 2736-46.
116. Mendrysa SM,McElwee MK,Michalowski J,O'Leary KA,Young KM,Perry ME.mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.Mol Cell Biol. 2003;23 (2): 462-72.
117. Mendrysa SM,O'Leary KA,McElwee MK, et al.Tumor suppression and normal aging in mice with constitutively high p53 activity.Genes Dev. 2006;20 (1): 16-21.
118. Maier B,Gluba W,Bernier B, et al.Modulation of mammalian life span by the short isoform of p53.Genes Dev. 2004;18 (3): 306-19.
119. Hinkal GW,Gatza CE,Parikh N,Donehower LA.Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging.Mech Ageing Dev. 2009;130 (4): 262-71.
120. Matheu A,Maraver A,Serrano M.The Arf/p53 pathway in cancer and aging.Cancer Res. 2008;68 (15): 6031-4.
121. Purdie CA,Harrison DJ,Peter A, et al.Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.Oncogene. 1994;9 (2): 603-9.
122. Leontieva OV,Blagosklonny MV.DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.Aging (Albany NY). 2010;2 (12): 924-35.
123. Feng Z,Hu W,Teresky AK,Hernando E,Cordon-Cardo C,Levine AJ.Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations.Proc Natl Acad Sci U S A. 2007;104 (42): 16633-8.